Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment

Virology Journal

Volumn 8, Issue , 2011, Pages

  Wang, Zhao ^a   Wu, Xiao Ling ^a   Zeng, Wei Zheng ^a   Xu, Hui ^a   Zhang, Yong ^a   Qin, Jian Ping ^a   Jiang, Ming De ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

ADV plus LAM; chronic hepatitis B; LAM alone; retreatment

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CHEMICAL ANALYSIS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RECURRENT DISEASE; SEROCONVERSION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS STRAIN; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; METHODOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; TREATMENT WITHDRAWAL;

HEPATITIS B VIRUS;

ADENINE; ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; RECURRENCE; SALVAGE THERAPY; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 79961100515     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-388     Document Type: Article

References (22)

1. Viral hepatitis B. Lai CL, Ratziu V, Yuen MF, Poynard T, Lancet 2003 362 2089 2094 10.1016/S0140-6736(03)15108-2 14697813 (Pubitemid 38032767)
2. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Lavanchy D, J Viral Hepat 2004 11 97 107 10.1046/j.1365-2893.2003.00487.x 14996343 (Pubitemid 38365759)
3. Strategies for global prevention of hepatitis B virus infection. Van Damme P, Zanetti AR, Shouval D, Van Herck K, Adv Exp Med Biol 2010 659 175 188 10.1007/978-1-4419-0981-7-14 20204764
4. Chronic hepatitis B: update 2009. Lok AS, McMahon BJ, Hepatology 2009 50 661 662 10.1002/hep.23190 19714720
5. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF, Hepatology 2002 35 1522 1527 10.1053/jhep.2002.33638 12029639 (Pubitemid 34966908)
6. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Fattovich G, Rugge M, Brollo L, Pontisso P, Noventa F, Guido M, Alberti A, Realdi G, Hepatology 1986 6 167 172 10.1002/hep.1840060203 3957228 (Pubitemid 16144862)
7. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL, Gastroenterology 2010 139 491 498 10.1053/j.gastro.2010.03.059 20381492
8. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS, Hepatology 2000 32 803 806 10.1053/jhep.2000.16665 11003626
9. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, Han S, Kaymakoglu S, Tamez R, Yang J, Tenney D, Brett-Smith H, J Hepatol 2009 50 289 295 10.1016/j.jhep.2008.10.017 19070393
10. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E, Hepatology 2003 37 748 755 10.1053/jhep.2003.50117 12668966 (Pubitemid 36397384)
11. Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection. Ito K, Tanaka Y, Orito E, Hirashima N, Ide T, Hino T, Kumashiro R, Kato A, Nukaya H, Sakakibara K, Mukaide M, Ito H, Sata M, Ueda R, Mizokami M, Clin Infect Dis 2004 38 490 495 10.1086/380965 14765340 (Pubitemid 38250957)
12. Hepatitis B virus resistance to antiviral drugs: where are we going? Zoulim F, Liver Int 2011 31 Suppl 1 111 116 21205147
13. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009 50 227 242 10.1016/j.jhep.2008.10.001 19054588
14. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl) 2007 120 2159 2173
15. Viral quasi-species evolution during hepatitis Be antigen seroconversion. Lim SG, Cheng Y, Guindon S, Seet BL, Lee LY, Hu P, Wasser S, Peter FJ, Tan T, Goode M, Rodrigo AG, Gastroenterology 2007 133 951 958 10.1053/j.gastro.2007.06. 011 17854598 (Pubitemid 47381357)
16. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C, Hepatology 2007 46 254 265 10.1002/hep.21698 17596850 (Pubitemid 47171942)
17. Diagnosis of hepatitis B virus infection through serological and virological markers. Kao JH, Expert Rev Gastroenterol Hepatol 2008 2 553 562 10.1586/17474124.2.4.553 19072403
18. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Liu Y, Wang C, Zhong Y, Chen L, Li X, Ji D, Wang H, Xin S, Zoulim F, Xu D, Antivir Ther 2010 15 1185 1190 10.3851/IMP1679 21149926
19. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. Ijaz S, Arnold C, Dervisevic S, Mechurova J, Tatman N, Tedder RS, Naoumov NV, J Med Virol 2008 80 1160 1170 10.1002/jmv.21206 18461609 (Pubitemid 351705994)
20. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. Sanchez MJ, Buti M, Homs M, Palacios A, Rodriguez-Frias F, Esteban R, J Hepatol 2009 51 1091 1096 10.1016/j.jhep.2009.07.012 19836097
21. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Carey I, Harrison PM, Expert Opin Investig Drugs 2009 18 1655 1666 10.1517/13543780903241599 19852566
22. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Chen EQ, Wang LC, Lei J, Xu L, Tang H, Virol J 2009 6 163 10.1186/1743-422X-6-163 19818142